以色列 - 英文 - Ministry of Health

glaxo smith kline (israel) ltd - fluticasone furoate; umeclidinium as bromide; vilanterol as trifenatate - powder for inhalation pre-dispensed - vilanterol as trifenatate 22 mcg/inh; umeclidinium as bromide 55 mcg/inh; fluticasone furoate 184 mcg/inh - vilanterol, umeclidinium bromide and fluticasone furoate - asthmatrelegy ellipta 184/55/22 mcg is indicated for the maintenance treatment of asthma in patients aged 18 years and older. trelegy ellipta 184/55/22 mcg should be prescribed for patients who are not adequately controlled on maintenance asthma medication, such as an ics/laba.important limitations of usetrelegy ellipta 184/55/22 mcg is not indicated for the relief of acute asthma.trelegy ellipta 184/55/22 mcg is not indicated for patients with copd.

以色列 - 英文 - Ministry of Health

novartis israel ltd., israel - ceftazidime as pentahydrate - powder for solution for inj/inf - ceftazidime as pentahydrate 2 g/vial - ceftazidime - ceftazidime - fortum is indicated for the treatment of the infections listed below in adults and children including neonates (from birth).• nosocomial pneumonia• broncho-pulmonary infections in cystic fibrosis• bacterial meningitis• chronic suppurative otitis media• malignant otitis externa• complicated urinary tract infections• complicated skin and soft tissue infections• complicated intra-abdominal infections• bone and joint infections• peritonitis associated with dialysis in patient on capd.treatment of patients with bacteraemia that occurs in association with, or is suspected to be associated with, any of the infections listed above.ceftazidime may be used in the management of neutropenic patients with fever that is suspected to be due to a bacterial infection.ceftazidime may be used in the peri-operative prophylaxis of urinary tract infections for patients undergoing trans-urethral resection of the prostate (turp).the selection of ceftazidime should take into account its antibacterial spectrum, which is mainly restricted to aerobic gram negative bacteria.ceftazidime should be co-administered with other antibacterial agents whenever the possible range of causive bacteria would not fall within its spectrum of activity.consideration should be given to official guidelines on the appropriate use of antibacterial agents.

以色列 - 英文 - Ministry of Health

novartis israel ltd., israel - ceftazidime as pentahydrate - powder for solution for inj/inf - ceftazidime as pentahydrate 1 g/vial - ceftazidime - ceftazidime - fortum is indicated for the treatment of the infections listed below in adults and children including neonates (from birth).• nosocomial pneumonia• broncho-pulmonary infections in cystic fibrosis• bacterial meningitis• chronic suppurative otitis media• malignant otitis externa• complicated urinary tract infections• complicated skin and soft tissue infections• complicated intra-abdominal infections• bone and joint infections• peritonitis associated with dialysis in patient on capd.treatment of patients with bacteraemia that occurs in association with, or is suspected to be associated with, any of the infections listed above.ceftazidime may be used in the management of neutropenic patients with fever that is suspected to be due to a bacterial infection.ceftazidime may be used in the peri-operative prophylaxis of urinary tract infections for patients undergoing trans-urethral resection of the prostate (turp).the selection of ceftazidime should take into account its antibacterial spectrum, which is mainly restricted to aerobic gram negative bacteria.ceftazidime should be co-administered with other antibacterial agents whenever the possible range of causive bacteria would not fall within its spectrum of activity.consideration should be given to official guidelines on the appropriate use of antibacterial agents.

欧盟 - 英文 - EMA (European Medicines Agency)

glaxosmithkline trading services - mepolizumab - asthma - drugs for obstructive airway diseases, - severe eosinophilic asthmanucala is indicated as an add-on treatment for severe refractory eosinophilic asthma in adults, adolescents and children aged 6 years and older .chronic rhinosinusitis with nasal polyps (crswnp)nucala is indicated as an add-on therapy with intranasal corticosteroids for the treatment of adult patients with severe crswnp for whom therapy with systemic corticosteroids and/or surgery do not provide adequate control.eosinophilic granulomatosis with polyangiitis (egpa)nucala is indicated as an add-on treatment for patients aged 6 years and older with relapsing-remitting or refractory eosinophilic granulomatosis with polyangiitis (egpa).hypereosinophilic syndrome (hes)nucala is indicated as an add-on treatment for adult patients with inadequately controlled hypereosinophilic syndrome without an identifiable non-haematologic secondary cause.

以色列 - 英文 - Ministry of Health

glaxo smith kline (israel) ltd - epoprostenol as sodium - powder for solution for infusion - epoprostenol as sodium 1.5 mg/vial - epoprostenol - epoprostenol - flolan is indicated for the treatment of pulmonary arterial hypertension (pah) (idiopathic or heritable pah and pah associated with connective tissue diseases) in patients with who functional class iii-iv symptoms to improve exercise capacity

以色列 - 英文 - Ministry of Health

glaxo smith kline (israel) ltd - epoprostenol as sodium - powder for solution for infusion - epoprostenol as sodium 0.5 mg/vial - epoprostenol - epoprostenol - flolan is indicated for the treatment of pulmonary arterial hypertension (pah) (idiopathic or heritable pah and pah associated with connective tissue diseases) in patients with who functional class iii-iv symptoms to improve exercise capacity

以色列 - 英文 - Ministry of Health

glaxo smith kline (israel) ltd - abacavir as sulfate - film coated tablets - abacavir as sulfate 300 mg - abacavir - abacavir - ziagen is indicated in antiretroviral combination therapy for the treatment of human immunodeficiency virus (hiv) infected .28/10/2018 בקשה לשינוי משטר מינון

以色列 - 英文 - Ministry of Health

glaxo smith kline (israel) ltd - diphtheria toxoid; filamentous haemagglutinin (fha); pertactin (prn or 69 kda omp); pertussis toxoid (pt); tetanus toxoid - suspension for injection - diphtheria toxoid nlt 2 iu / 0.5 ml; tetanus toxoid nlt 20 iu / 0.5 ml; filamentous haemagglutinin (fha) 8 mcg / 0.5 ml; pertussis toxoid (pt) 8 mcg / 0.5 ml; pertactin (prn or 69 kda omp) 2.5 mcg / 0.5 ml - tetanus toxoid, combinations with diphtheria toxoid - tetanus toxoid, combinations with diphtheria toxoid - for booster vaccination against diphtheria, tetanus and pertussis of individuals from the age of four years onwards.the administration of boostrix should be based on official recommendations

以色列 - 英文 - Ministry of Health

glaxo smith kline (israel) ltd - hepatitis a virus antigen, inactivated - suspension for injection - hepatitis a virus antigen, inactivated 1440 e.l.u/ml - hepatitis a, inactivated, whole virus - hepatitis a, inactivated, whole virus - active immunisation against infections caused by hepatitis a virus.the vaccine is particularly indicated for those at increased risk of infection or transmission.

以色列 - 英文 - Ministry of Health

glaxo smith kline (israel) ltd - hepatitis a virus antigen, inactivated - suspension for injection - hepatitis a virus antigen, inactivated 720 e.l.u / 0.5 ml - hepatitis a, inactivated, whole virus - hepatitis a, inactivated, whole virus - active immunisation against hav infection from 1 year up to and including 15 years of age. the vaccine is particularly indicated for those at increased risk of infection or transmission. it is also indicated for use during outbreaks of hepatitis a infection.